Geftinat 250mg is an oral anticancer medication used to treat non-small cell lung cancer (NSCLC) with EGFR mutations. It works by blocking signals that promote the growth of cancer cells.
Geftinat 250mg, manufactured by Natco Pharma Ltd., contains Gefitinib, a targeted therapy that inhibits EGFR tyrosine kinase. It is commonly prescribed as a first-line treatment in advanced EGFR-mutated NSCLC, helping manage tumor growth and improve survival.
Uses:
Advanced or metastatic non-small cell lung cancer (NSCLC)
EGFR mutation-positive lung tumors
First-line therapy in eligible NSCLC patients
Maintenance therapy after initial treatment response
Second-line treatment in case of chemotherapy resistance
Off-label research use in other EGFR-dependent tumors
Storage Instructions:
Store at 15°C–30°C (room temperature)
Keep in a cool, dry place, protected from moisture and sunlight
